RT Journal Article
T1 Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients.
A1 Alcaraz, Antonio
A1 Rodríguez-Antolín, Alfredo
A1 Carballido-Rodríguez, Joaquín
A1 Castro-Díaz, David
A1 Medina-Polo, José
A1 Fernández-Gómez, Jesús M
A1 Ficarra, Vincenzo
A1 Palou, Joan
A1 Ponce de León Roca, Javier
A1 Angulo, Javier C
A1 Esteban-Fuertes, Manuel
A1 Cózar-Olmo, José M
A1 Pérez-León, Noemí
A1 Molero-García, José M
A1 Fernández-Pro Ledesma, Antonio
A1 Brenes-Bermúdez, Francisco J
A1 Manasanch, José
AB In a subset analysis of data from a 6-month, multicenter, non-interventional study, we compared change in symptoms and quality of life (QoL), and treatment tolerability, in men with moderate to severe lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) receiving tamsulosin (TAM, 0.4 mg/day) or the hexanic extract of Serenoa repens (HESr, 320 mg/day) as monotherapy. Symptoms and QoL were assessed using the IPSS and BII questionnaires, respectively. Patients in the treatment groups were matched using two statistical approaches (iterative and propensity score matching). Within the iterative matching approach, data was available from a total of 737 patients (353 TAM, 384 HESr). After 6 months, IPSS scores improved by a mean (SD) of 5.0 (4.3) points in the TAM group and 4.5 (4.7) points in the HESr group (p = 0.117, not significant). Improvements in QoL were equivalent in the two groups. TAM patients reported significantly more adverse effects than HESr patients (14.7% vs 2.1%; p 
YR 2021
FD 2021-09-29
LK https://hdl.handle.net/10668/26279
UL https://hdl.handle.net/10668/26279
LA en
DS RISalud
RD Apr 17, 2025